Showing results (2881-2890 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|April 1, 2021
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in SwitzerlandNadine Schur, Kapil Gudala, Umakanth Vudumula, et al.
Pharmacoeconomics|April 9, 2015
Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology AppraisalMatt Stevenson, Abdullah Pandor, John W Stevens, et al.
Pharmacoeconomics|July 31, 2020
Taking the Analysis of Trial-Based Economic Evaluations to the Next Level: The Importance of Accounting for ClusteringMohamed El Alili, Johanna M van Dongen, Keith S Goldfeld, et al.
Pharmacoeconomics|May 5, 2023
Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic ReviewHans Van Remoortel, Hans Scheers, Bert Avau, et al.
Pharmacoeconomics|April 21, 2023
Productivity Loss Across Socioeconomic Groups Among Patients With Low Back Pain or Osteoarthritis: Estimates Using the Friction-Cost Approach in NorwayJohan A Liseth Hansen, Thomas Fast, Knut Reidar Wangen
Pharmacoeconomics|April 22, 2023
Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United StatesMickaël Hiligsmann, Stuart S Silverman, Andrea J Singer, et al.
Pharmacoeconomics|April 23, 2023
Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the LiteratureDaniel D Joyce, Vidit Sharma, Stephen B Williams
Pharmacoeconomics|May 17, 2023
Accounting for Nonhealth and Future Costs in Cost-Effectiveness Analysis: Distributional Impacts of a US Cancer Prevention StrategyDavid D Kim
Pharmacoeconomics|March 5, 2015
Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetesJinsong Geng, Hao Yu, Yiwei Mao, et al.
Pharmacoeconomics|August 18, 2020
Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry DataKoen Degeling, Hui-Li Wong, Hendrik Koffijberg, et al.
Pageof 336